SynthesisBMJ open2014
Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes.
Synthesis in BMJ open, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- The Expanding Role of GLP-1 Receptor Agonists: Advancing Clinical Outcomes in Metabolic and Mental Health.Current issues in molecular biology · 2025Review
- Current Status of Glucagon-like Peptide-1 Receptor Agonists in Metabolic Dysfunction-associated Steatotic Liver Disease: A Clinical Perspective.Journal of clinical and translational hepatology · 2025Review
- Metabolic Dysfunction-associated Steatotic Liver Disease and Type 2 Diabetes: A Deadly Synergy.TouchREVIEWS in endocrinology · 2024Article
- Hepatic glucose metabolism in the steatotic liver.Nature reviews. Gastroenterology & hepatology · 2024Review
- Review
- GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives.International journal of molecular sciences · 2023Review
- Non-alcoholic fatty liver disease, metabolic syndrome, and type 2 diabetes mellitus: where do we stand today?Archives of medical science : AMS · 2023Article
- Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease.Current obesity reports · 2022Review
- Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations.Cardiovascular therapeutics · 2022Review
- AGL9: A Novel Hepatoprotective Peptide from the Larvae of Edible Insects Alleviates Obesity-Induced Hepatic Inflammation by Regulating AMPK/Nrf2 Signaling.Foods (Basel, Switzerland) · 2021Article
- Liver-targeting drugs and their effect on blood glucose and hepatic lipids.Diabetologia · 2021Review
- Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real-world data analysis.Liver international : official journal of the International Association for the Study of the Liver · 2021Article
- Review
- NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations.Journal of clinical medicine · 2021Review
- Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease.Clinical and molecular hepatology · 2020Review
- Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update.World journal of hepatology · 2020Review
- Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH.International journal of molecular sciences · 2020Review
- Post-transplant diabetes mellitus and preexisting liver disease - a bidirectional relationship affecting treatment and management.World journal of gastroenterology · 2020Review
- Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2019Review
- From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options.JHEP reports : innovation in hepatology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the effects of the glucagon-like peptide-1 receptor agonist lixisenatide on elevated liver blood tests in patients with type 2 diabetes.
designSystematic review. DATA SOURCES: Electronic and manual searches were combined. STUDY SELECTION: Randomised controlled trials (RCTs) on lixisenatide versus placebo or active comparators for type 2 diabetes were included.
participantsIndividual patient data were retrieved to calculate outcomes for patients with elevated liver blood tests.
main outcome measuresNormalisation of alanine aminotransferase (ALT) and aspartate aminotransferase (AST). DATA SYNTHESIS: The results of included trials were combined in meta-analyses. Sequential, subgroup and regression analyses were performed to evaluate heterogeneity and bias.
resultsWe included 12 RCTs on lixisenatide versus placebo and 3 RCTs with the active comparators liraglutide, exenatide or sitagliptin. The mean treatment duration was 29 weeks. Lixisenatide increased the proportion of patients with normalisation of ALT (risk difference: 0.07; 95% CI 0.01 to 0.14; number needed to treat: 14 patients, p=0.042). The effect was not confirmed in sequential analysis. No effects of lixisenatide were identified on AST, alkaline phosphatase or bilirubin. No evidence of bias was identified. Mixed effect multilevel meta-regression analyses suggest that the benefit of lixisenatide on ALT was limited to patients who were overweight or obese.
conclusionsThis review suggests that lixisenatide increases the proportion of obese or overweight patients with type 2 diabetes who achieve normalisation of ALT. Additional research is needed to determine if the findings translate to clinical outcome measures. TRIAL REGISTRATION NUMBER: PROSPERO; CRD42013005779.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.